Related Experiment Videos
Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey
Abstract:
The study concerns symptoms and behavioral characteristics induced by MPTP in a 20-year-old Macaca cynomolgus fascicularis, their evolution over 7 months, and the animal's response to 1-dopa treatment. The symptoms which the animal developed include those that have been described earlier in Macaca mulatta and Saimiri sciureus, i.e., rigidity, action tremor, postural tremor, postural flexion, hypokinesia, and bradykinesia. In addition, however, the animal developed a 3.8 Hz resting tremor which in humans is pathognomonic of Parkinson's disease, as well as cogwheeling, the glabellar tap sign, drooling, impaired ability to relax, and many other symptoms. Also unlike previously described MPTP monkeys, the animal's symptoms neither improved spontaneously, nor did they remain stable shortly after MPTP injection. Instead, symptoms steadily progressed to reach a severe status 2 months after MPTP, and further progression was apparent after another 5 months. Therapeutic responses to 1-dopa required accumulation of or kindling by the 100 mg unit doses that were spaced 4 hr apart, were often organized in time as ON episodes that alternated with OFF episodes, and were associated with dyskinesias and bizarre behavior. Of particular interest is that the animal showed kinesia paradoxa which, in humans, constitutes a feature that is unique to Parkinson's disease among the extrapyramidal disorders. In addition to available evidence, the present findings validate the syndrome induced by MPTP in monkey as an animal analogue of Parkinson's disease. Taxonomic category, age, and the occurrence of shock in response to MPTP are discussed as variables that may possibly co-determine the pathology which MPTP may induce in monkey.
Insights
MPTP induced Parkinson
Area of Science:
- Neuroscience
- Primate Models
- Parkinson's Disease Research
Background:
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin known to induce Parkinsonism in primates.
- Previous studies have documented MPTP-induced symptoms in various primate species, but individual responses can vary.
Purpose of the Study:
- To detail the progressive symptoms and behavioral changes in a Macaca cynomolgus fascicularis monkey after MPTP administration.
- To evaluate the therapeutic response to L-DOPA treatment over a 7-month period.
- To investigate the potential of this MPTP-induced model as an analogue for Parkinson's disease.
Main Methods:
- Administration of MPTP to a 20-year-old Macaca cynomolgus fascicularis.
- Longitudinal observation of symptom evolution over 7 months.
- Assessment of behavioral and motor responses to L-DOPA treatment.
Main Results:
- The monkey developed a wide range of Parkinsonian symptoms, including rigidity, tremors (resting and action), bradykinesia, and postural abnormalities.
- Unlike some previous reports, symptoms showed continuous progression, worsening over the 7-month study period.
- L-DOPA treatment elicited fluctuating ON-OFF episodes, dyskinesias, and paradoxical kinesia, a feature unique to Parkinson's disease in humans.
- The animal exhibited a 3.8 Hz resting tremor, pathognomonic of Parkinson's disease in humans.
Conclusions:
- The MPTP-induced syndrome in this Macaca cynomolgus fascicularis closely mimics human Parkinson's disease, validating its use as an animal model.
- The progressive nature of symptoms and specific motor deficits, including resting tremor and paradoxical kinesia, strengthen its relevance.
- Factors such as species, age, and initial shock response may influence MPTP-induced pathology in non-human primates.